<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943668</url>
  </required_header>
  <id_info>
    <org_study_id>9422</org_study_id>
    <secondary_id>NCI-2016-01457</secondary_id>
    <secondary_id>9422</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT02943668</nct_id>
  </id_info>
  <brief_title>Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase II Study of Deferasirox in Patients With Myelodysplastic Syndromes Who Are Anemic With Iron Overload</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well deferasirox works in treating patients with very low,
      low, or intermediate-risk anemia or myelodysplastic syndrome that depends on red blood cell
      transfusions. Deferasirox may treat too much iron in the blood caused by blood transfusions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the activity of iron chelation therapy (ICT) with deferasirox, in patients with
      anemia due to myelodysplastic syndrome (MDS).

      SECONDARY OBJECTIVES:

      I. Reduction in red blood cell (RBC) transfusion requirements. II. Hematologic improvement.
      III. Change in serum ferritin levels from baseline to the end of the study as measured on a
      monthly basis.

      IV. Safety and tolerability of deferasirox.

      EXPLORATORY OBJECTIVES:

      I. Blood and marrow samples will be taken to study erythropoiesis and the impact of iron
      overload on erythropoiesis.

      OUTLINE: Patients receive deferasirox orally (PO) once daily (QD). Treatment continues for up
      to 52 weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to low accrual
  </why_stopped>
  <start_date type="Actual">March 2, 2017</start_date>
  <completion_date type="Actual">December 17, 2018</completion_date>
  <primary_completion_date type="Actual">December 17, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients That Achieve Erythroid Hematologic Improvement.</measure>
    <time_frame>At 6 months</time_frame>
    <description>As defined by the modified International Working Group (IWG) response criteria:
Erythroid response (pretreatment, &lt;11 g/dL):
Hgb increase by ≥ 1.5 g/dL
Relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 wk compared with the pretreatment transfusion number in the previous 8 wk. Only RBC transfusions given for a Hgb of ≤ 0.9 g/dL pretreatment will count in the RBC transfusion response evaluation.
Platelet response (pretreatment, &lt; 100 x 10^9/L)
Absolute increase of ≥ 30 x 10^9/L for patients starting with &gt; 20 x 10^9/L platelets
Increase from &lt; 20 x 10^9/L to &gt; 20 x 10^9/L and by at least 100%
Neutrophil response (pretreatment, &lt; 1.0 x 10^9/L)
1) At least 100% increase and an absolute increase &gt; 0.5 x 10^9/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Red Blood Cell (RBC) Transfusion Requirements</measure>
    <time_frame>Baseline up to 12 months</time_frame>
    <description>Assessed monthly for up to twelve months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Ferritin Levels</measure>
    <time_frame>Baseline up to 12 months</time_frame>
    <description>Assessed monthly for up to twelve months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Achieve Granulocyte or Platelet Hematologic Improvement</measure>
    <time_frame>At 6 months</time_frame>
    <description>As defined by the modified International Working Group (IWG) response criteria:
Erythroid response (pretreatment, &lt;11 g/dL):
Hgb increase by ≥ 1.5 g/dL
Relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 wk compared with the pretreatment transfusion number in the previous 8 wk. Only RBC transfusions given for a Hgb of ≤ 0.9 g/dL pretreatment will count in the RBC transfusion response evaluation.
Platelet response (pretreatment, &lt; 100 x 10^9/L)
Absolute increase of ≥ 30 x 10^9/L for patients starting with &gt; 20 x 10^9/L platelets
Increase from &lt; 20 x 10^9/L to &gt; 20 x 10^9/L and by at least 100%
Neutrophil response (pretreatment, &lt; 1.0 x 10^9/L)
1) At least 100% increase and an absolute increase &gt; 0.5 x 10^9/L</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Anemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (deferasirox)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (deferasirox)</arm_group_label>
    <other_name>Exjade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (deferasirox)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving written informed consent prior to any study-specific procedures

          -  Diagnosis of MDS as defined by the World Health Organization (WHO) diagnostic criteria

          -  Have very low, low or intermediate-risk disease by the Revised International
             Prognostic Scoring System (IPSS-R)

          -  Baseline serum ferritin level &gt;= 100 ng/mL

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Anemia defined as: hemoglobin =&lt; 10.0 g/dL

          -  Bilirubin =&lt; 1.5 times upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =&lt; 3.5 times ULN

          -  Serum creatinine =&lt; 1.5 x ULN

          -  Estimated glomerular filtration rate (GFR) &gt; 40 mL/min

          -  Males and females with reproductive potential must agree to use medically approved
             contraceptive precautions during the study and for 3 months following the last dose of
             deferasirox

               -  Women of child-bearing potential, defined as all women physiologically capable of
                  becoming pregnant, unless they are using effective methods of contraception
                  during dosing of study treatment; effective contraception methods include:

                    -  Placement of an intrauterine device (IUD) or intrauterine system (IUS)

                    -  Barrier methods of contraception: condom or occlusive cap (diaphragm or
                       cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal
                       suppository

                    -  Total abstinence or (when this is in line with the preferred and usual
                       lifestyle of the subject); periodic abstinence (e.g., calendar, ovulation,
                       symptothermal, post-ovulation methods) and withdrawal are not acceptable
                       methods of contraception

                    -  Female sterilization (have had surgical bilateral oophorectomy with or
                       without hysterectomy) or tubal ligation at least six weeks before taking
                       study treatment; in case of oophorectomy alone, only when the reproductive
                       status of the woman has been confirmed by follow up hormone level assessment

                    -  Male sterilization (at least 6 months prior to screening); for female
                       subjects on the study, the vasectomized male partner should be the sole
                       partner for that subject

               -  Women are considered post-menopausal and not of child bearing potential if they
                  have had 12 months of natural (spontaneous) amenorrhea with an appropriate
                  clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have
                  had surgical bilateral oophorectomy (with or without hysterectomy) or tubal
                  ligation at least six weeks ago; in the case of oophorectomy alone, only when the
                  reproductive status of the woman has been confirmed by follow up hormone level
                  assessment is she considered not of child bearing potential; sexually active
                  males must use a condom during intercourse while taking drug and for 28 days
                  after stopping study medication and should not father a child in this period; a
                  condom is required to be used also by vasectomized men in order to prevent
                  delivery of the drug via seminal fluid

          -  Females with childbearing potential* must have had a negative urine or serum pregnancy
             test =&lt; 7 days before the first dose of deferasirox and must also not be breastfeeding

          -  Reliable and willing to make themselves available for the duration of the study and
             are willing to follow study procedures

        Exclusion Criteria:

          -  If the patient is currently receiving erythroid stimulating agents (ESA) with plans to
             continue during study, less than 2 months duration of ESA prior to starting study drug
             and no dose escalation within 2 months of start of study drug

          -  If the patient is being treated with granulocyte-colony stimulating factor (GCSF)
             and/or a TPO-mimetic (for example, eltrombopag or romiplostim) with plans to continue
             during the study: Less than 2 months duration of GCSF or the TPO-mimetic treatment
             prior to starting study drug; or GCSF and/or TPO-mimetic has been added to ESA therapy
             within 2 months of start of study drug

          -  If patient is being treated with lenalidomide with plans to continue during the study:
             Stable dose for less than 3 months prior to start of study drug

          -  If patient is being treated with hypomethylating agents (HMA) (for example,
             azacitidine or decitabine) with plans to continue during the study: Stable dose for
             less than 6 months prior to start of study drug

          -  Currently enrolled in, or discontinued within the last 14 days from a clinical trial
             involving an investigational product or non-approved use of a drug, or concurrently
             enrolled in any other type of medical research judged not to be scientifically or
             medically compatible with this study

          -  Presence of &gt;= 10% blast by morphologic examination of bone marrow aspirate or biopsy

          -  Platelets =&lt; 50,000

          -  Microcytosis on screening blood cell count (CBC) (mean corpuscular volume [MCV] &lt; 81
             fL)

          -  Active gastrointestinal (GI) ulceration or hemorrhage

          -  Have a serious preexisting medical condition that, in the opinion of the investigator
             would preclude participation in the study (for example a GI disorder causing
             clinically significant symptoms such as nausea, vomiting, and diarrhea, or
             malabsorption syndrome) or that would result in a life expectancy of less than 1 year

          -  Known hypersensitivity to deferasirox

          -  History of non-transfusional hemosiderosis

          -  Prior hematopoietic stem cell transplant for the diagnosis of MDS

          -  A second primary malignancy that in the judgment of the principal investigator (PI) or
             designee may affect the interpretation of results

          -  Have an active fungal, bacterial, and/or known viral infection including human
             immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis

          -  Currently using aluminum-containing antacid products

          -  History of clinically significant auditory or ocular toxicity with ICT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Scott</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <results_first_submitted>June 12, 2020</results_first_submitted>
  <results_first_submitted_qc>June 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2020</results_first_posted>
  <disposition_first_submitted>April 23, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 23, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 28, 2020</disposition_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02943668/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Deferasirox)</title>
          <description>Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
Deferasirox: Given PO
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Deferasirox)</title>
          <description>Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
Deferasirox: Given PO
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients That Achieve Erythroid Hematologic Improvement.</title>
        <description>As defined by the modified International Working Group (IWG) response criteria:
Erythroid response (pretreatment, &lt;11 g/dL):
Hgb increase by ≥ 1.5 g/dL
Relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 wk compared with the pretreatment transfusion number in the previous 8 wk. Only RBC transfusions given for a Hgb of ≤ 0.9 g/dL pretreatment will count in the RBC transfusion response evaluation.
Platelet response (pretreatment, &lt; 100 x 10^9/L)
Absolute increase of ≥ 30 x 10^9/L for patients starting with &gt; 20 x 10^9/L platelets
Increase from &lt; 20 x 10^9/L to &gt; 20 x 10^9/L and by at least 100%
Neutrophil response (pretreatment, &lt; 1.0 x 10^9/L)
1) At least 100% increase and an absolute increase &gt; 0.5 x 10^9/L</description>
        <time_frame>At 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Deferasirox)</title>
            <description>Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
Deferasirox: Given PO
Laboratory Biomarker Analysis: Correlative studies
Of the two participants on the study, none achieved erythroid hematologic improvement as defined by the modified IWG response criteria at 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients That Achieve Erythroid Hematologic Improvement.</title>
          <description>As defined by the modified International Working Group (IWG) response criteria:
Erythroid response (pretreatment, &lt;11 g/dL):
Hgb increase by ≥ 1.5 g/dL
Relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 wk compared with the pretreatment transfusion number in the previous 8 wk. Only RBC transfusions given for a Hgb of ≤ 0.9 g/dL pretreatment will count in the RBC transfusion response evaluation.
Platelet response (pretreatment, &lt; 100 x 10^9/L)
Absolute increase of ≥ 30 x 10^9/L for patients starting with &gt; 20 x 10^9/L platelets
Increase from &lt; 20 x 10^9/L to &gt; 20 x 10^9/L and by at least 100%
Neutrophil response (pretreatment, &lt; 1.0 x 10^9/L)
1) At least 100% increase and an absolute increase &gt; 0.5 x 10^9/L</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Red Blood Cell (RBC) Transfusion Requirements</title>
        <description>Assessed monthly for up to twelve months.</description>
        <time_frame>Baseline up to 12 months</time_frame>
        <population>Data for the 2 participants is presented as 2 different groups to show the individual RBC transfusion requirements per month, at each point in time</population>
        <group_list>
          <group group_id="O1">
            <title>Patient 1</title>
            <description>Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
Deferasirox: Given PO
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Patient 2</title>
            <description>Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
Deferasirox: Given PO
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Red Blood Cell (RBC) Transfusion Requirements</title>
          <description>Assessed monthly for up to twelve months.</description>
          <population>Data for the 2 participants is presented as 2 different groups to show the individual RBC transfusion requirements per month, at each point in time</population>
          <units>RBC transfusions/month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Transfusion requirement at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transfusion requirement at time off-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Ferritin Levels</title>
        <description>Assessed monthly for up to twelve months.</description>
        <time_frame>Baseline up to 12 months</time_frame>
        <population>Data for the 2 participants is presented as 2 different groups to show the individual serum ferritin levels at each point in time</population>
        <group_list>
          <group group_id="O1">
            <title>Patient 1</title>
            <description>Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
Deferasirox: Given PO
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Patient 2</title>
            <description>Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
Deferasirox: Given PO
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Ferritin Levels</title>
          <description>Assessed monthly for up to twelve months.</description>
          <population>Data for the 2 participants is presented as 2 different groups to show the individual serum ferritin levels at each point in time</population>
          <units>ng/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6025"/>
                    <measurement group_id="O2" value="755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6637"/>
                    <measurement group_id="O2" value="778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6010"/>
                    <measurement group_id="O2" value="827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6405"/>
                    <measurement group_id="O2" value="583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22360"/>
                    <measurement group_id="O2" value="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7252"/>
                    <measurement group_id="O2" value="652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5697"/>
                    <measurement group_id="O2" value="776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4832"/>
                    <measurement group_id="O2" value="880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4054"/>
                    <measurement group_id="O2" value="NA">Patient went off-study after 7 months.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3933"/>
                    <measurement group_id="O2" value="NA">Patient went off-study after 7 months.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3728"/>
                    <measurement group_id="O2" value="NA">Patient went off-study after 7 months.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Patient went off-study after 10 months.</measurement>
                    <measurement group_id="O2" value="NA">Patient went off-study after 7 months.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Patient went off-study after 10 months.</measurement>
                    <measurement group_id="O2" value="NA">Patient went off-study after 7 months.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Achieve Granulocyte or Platelet Hematologic Improvement</title>
        <description>As defined by the modified International Working Group (IWG) response criteria:
Erythroid response (pretreatment, &lt;11 g/dL):
Hgb increase by ≥ 1.5 g/dL
Relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 wk compared with the pretreatment transfusion number in the previous 8 wk. Only RBC transfusions given for a Hgb of ≤ 0.9 g/dL pretreatment will count in the RBC transfusion response evaluation.
Platelet response (pretreatment, &lt; 100 x 10^9/L)
Absolute increase of ≥ 30 x 10^9/L for patients starting with &gt; 20 x 10^9/L platelets
Increase from &lt; 20 x 10^9/L to &gt; 20 x 10^9/L and by at least 100%
Neutrophil response (pretreatment, &lt; 1.0 x 10^9/L)
1) At least 100% increase and an absolute increase &gt; 0.5 x 10^9/L</description>
        <time_frame>At 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Deferasirox)</title>
            <description>Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
Deferasirox: Given PO
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Achieve Granulocyte or Platelet Hematologic Improvement</title>
          <description>As defined by the modified International Working Group (IWG) response criteria:
Erythroid response (pretreatment, &lt;11 g/dL):
Hgb increase by ≥ 1.5 g/dL
Relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 wk compared with the pretreatment transfusion number in the previous 8 wk. Only RBC transfusions given for a Hgb of ≤ 0.9 g/dL pretreatment will count in the RBC transfusion response evaluation.
Platelet response (pretreatment, &lt; 100 x 10^9/L)
Absolute increase of ≥ 30 x 10^9/L for patients starting with &gt; 20 x 10^9/L platelets
Increase from &lt; 20 x 10^9/L to &gt; 20 x 10^9/L and by at least 100%
Neutrophil response (pretreatment, &lt; 1.0 x 10^9/L)
1) At least 100% increase and an absolute increase &gt; 0.5 x 10^9/L</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Enrollment through 30 days after the last administration of the study treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Deferasirox)</title>
          <description>Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
Deferasirox: Given PO
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 4.03</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE 4.03</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia- due to acute blood loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>A-fib w/ rapid ventricular rate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostrid Difficile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture- Lft. Lateral Tibia Plateau</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fracture- Lft. Second Metatarsal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fracture- Lft. Wrist</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Alanine Amniotransferase- increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Asparate Aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatine/ urine protein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bart Scott</name_or_title>
      <organization>Fred Hutch Cancer Research Center</organization>
      <phone>206.667.1990</phone>
      <email>bscott@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

